Mark van Eldijk is Business Unit Director of Nanomedicines at Ardena. He combines scientific expertise in nanomedicine development and nanoparticle technologies with experience in strategic leadership, business development, and pharmaceutical CMC.
Mark joined Ardena in 2016 as a Scientist and Project Leader before transitioning into business development and later into his current leadership role. At Ardena, he leads multidisciplinary teams focused on the development and manufacture of innovative nanomedicine products, including lipid-based, polymeric, and metal-based nanoparticles carrying a broad range of therapeutic payloads such as cytotoxics, oligonucleotides, mRNA, peptides, and proteins. His expertise includes nanomedicine development, polymer chemistry, nanoparticle characterization, customer relationship management, and pharmaceutical development strategy.
Mark obtained his PhD in Bio-organic Chemistry from Radboud University Nijmegen, where his research focused on the design and preparation of biopolymer-based nanoparticles. He subsequently worked as a postdoctoral research fellow at the California Institute of Technology and has authored more than 20 peer-reviewed scientific publications.
